Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.31 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8576655 | 0.85 | PDE2A (0.35) | ALDH1A1CYP3A4CYP2D6ALOX15MAPK1 | |
| SCHEMBL6646409 | 0.83 | — | — | |
| SCHEMBL26273251 | 0.83 | — | — | |
| SCHEMBL6644895 | 0.82 | — | — | |
| SCHEMBL6643185 | 0.82 | PDE2A (0.40) | ALDH1A1CYP3A4CYP2D6ALOX15MAPK1 | |
| SCHEMBL13209404 | 0.82 | DGAT1 (0.33) | P2RX3P2RX2 | |
| SCHEMBL8580032 | 0.80 | CYP11B1 (0.34) | ALDH1A1CYP3A4CYP2D6ALOX15MAPK1 | |
| SCHEMBL6641950 | 0.79 | ALDH1A1 (0.33) | ALDH1A1CYP3A4CYP2D6ALOX15MAPK1 | |
| SCHEMBL27407435 | 0.79 | — | — | |
| SCHEMBL8581484 | 0.75 | ALDH1A1 (0.31) | ALDH1A1CYP3A4CYP2D6ALOX15MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023064345-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | VANQUA BIO, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
| US-20230026466-A1 | WDR5 INHIBITORS AND MODULATORS | VANDERBILT UNIVERSITY | 2023-01-26 | — | — | US | disclosed |
| EP-4122934-A1 | ORGANIC ELECTROLUMINESCENT MATERIAL AND DEVICE | Beijing Summer Sprout Technology Co., Ltd. (CN) | 2023-01-25 | — | — | EP | disclosed |
| US-20230012362-A1 | WDR5 INHIBITORS AND MODULATORS | VANDERBILT UNIVERSITY | 2023-01-12 | — | — | US | disclosed |
| US-20220009907-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) | 2022-01-13 | — | — | US | disclosed |
| US-11136309-B2 | Metalloenzyme inhibitor compounds | PHASEBIO PHARMACEUTICALS, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20200392112-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) | 2020-12-17 | — | — | US | disclosed |
| US-20180186773-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) | 2018-07-05 | — | — | US | disclosed |
| US-8114879-B2 | 4-piperazine-4-piperidine-1-ketone derivatives; graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis; human immunodeficiency viricides | SCHERING CORPORATION (US) | 2012-02-14 | — | — | US | disclosed |
| US-7825121-B2 | Piperazine derivatives useful as CCR5 antagonists | SCHERING CORPORATION (US) | 2010-11-02 | — | — | US | disclosed |
| US-7825121-B2 | Piperazine derivatives useful as CCR5 antagonists | SCHERING CORPORATION (US) | 2010-11-02 | — | — | US | disclosed |
| US-20080188485-A1 | PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORPORATION | 2008-08-07 | — | — | US | disclosed |
| US-7384944-B2 | Piperazine derivatives useful as CCR5 antagonists | SCHERING CORPORATION (US) | 2008-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188485-A1 | PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | CCR5, CXCR3, CCR2 | ALDH1A1 2736/4885CYP3A4 792/4885CYP2D6 1138/4885 |
| US-20200392112-A1 | METALLOENZYME INHIBITOR COMPOUNDS | SOD1, RNASE1, FECH | ALDH1A1 457/4885CYP3A4 863/4885CYP2D6 946/4885 |
| US-20220009907-A1 | METALLOENZYME INHIBITOR COMPOUNDS | SOD1, RNASE1, FECH | ALDH1A1 457/4885CYP3A4 863/4885CYP2D6 946/4885 |
| US-20230026466-A1 | WDR5 INHIBITORS AND MODULATORS | WDR5, WDR1, WDR3 | ALDH1A1 3815/4885CYP3A4 4489/4885CYP2D6 4154/4885 |
| US-20230012362-A1 | WDR5 INHIBITORS AND MODULATORS | WDR5, WDR1, WDR77 | ALDH1A1 3516/4885CYP3A4 4410/4885CYP2D6 4209/4885 |
| US-20180186773-A1 | METALLOENZYME INHIBITOR COMPOUNDS | SOD1, RNASE1, FECH | ALDH1A1 457/4885CYP3A4 863/4885CYP2D6 946/4885 |
| US-11136309-B2 | Metalloenzyme inhibitor compounds | SOD1, RNASE1, FECH | ALDH1A1 457/4885CYP3A4 863/4885CYP2D6 946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.